Thank you to our research participants, this would not have been possible without you!

SCYNEXIS Reports Positive Top-Line Results from First Phase 3 Registration Study of Oral Ibrexafungerp in Vulvovaginal Candidiasis (VANISH-303)

JERSEY CITY, N.J., Nov. 7, 2019 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced positive top-line results for its Phase 3 VANISH-303 study investigating the safety and efficacy of oral ibrexafungerp…

AGILE THERAPEUTICS ANNOUNCES FAVORABLE OUTCOME OF FDA ADVISORY COMMITTEE MEETING FOR ITS INVESTIGATIONAL TRANSDERMAL CONTRACEPTIVE PATCH, TWIRLA® (AG200-15)

PRINCETON, N.J., Oct. 30, 2019 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, announced a positive outcome from today’s meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) of the U.S. Food and Drug Administration (FDA). The BRUDAC met to discuss the Company’s New Drug Application (NDA) for its lead product candidate, Twirla® (AG200-15), an investigational combined hormonal contraceptive patch..

Myovant Sciences Announces 88% One-Year Response Rate in Positive Phase 3 LIBERTY Extension Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids

We are so thankful to the courageous women participants who have joined us on this journey and to you for your strong support of the LIBERTY program! We are so close to bringing this non-surgical therapy option to the millions of women suffering from Uterine Fibroids.

exeltis slynd oral contraceptive tablet

Exeltis USA announces the approval of Slynd™

Exeltis USA, Inc. a division of the global pharmaceutical group Insud Pharma, announced that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Slynd™ (pronounced “slind”) containing drospirenone 4 mg, an oral contraceptive tablet for pregnancy prevention.

Slynd™, a progestin-only pill (POP) is a novel estrogen-free oral contraceptive that is intended as a 24 active with 4 inactive tablet dosing regimen and also allows a 24-hour missed pill window. This not only can mean favorable safety and efficacy but an improved…

Evofem Biosciences, Inc. clinical trial of Amphora

Evofem Biosciences Reports Additional Data from Phase 3 ‘AMPOWER’ Study of Amphora® for Hormone-Free Birth Control

Evofem Biosciences, Inc. (NASDAQ: EVFM) (Evofem), a clinical-stage biopharmaceutical company, today reported additional data from its Phase 3 ‘AMPOWER’ clinical trial of Amphora® for the prevention of pregnancy. These findings reveal that the use of Amphora, a first-in-class investigational Multipurpose Vaginal pH Regulator (MVP-R™), may improve sexual satisfaction and have a positive impact on women’s sex lives.  The analysis also confirmed certain previously reported safety and efficacy data…

velicept solabegron overactive bladder (OAB)

Velicept Therapeutics Announces Positive Top-Line Phase 2B Results for Solabegron in the Treatment of Overactive Bladder (OAB)

Velicept Therapeutics, a privately-held specialty pharmaceutical company dedicated to the development of best-in-class compounds for the treatment of urological and gastrointestinal disorders, announced that its next generation beta-3 adrenoceptor agonist solabegron met the primary endpoint in VEL-2002, a Phase 2b study in patients with overactive bladder (OAB). In the study, twice-daily administration of solabegron demonstrated…

scynexis Phase 3 VANISH 303 Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC)

SCYNEXIS Completes Last-Patient/Last-Visit Ahead of Schedule in the First Phase 3 Study (VANISH 303) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC)

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced completion of the last-patient/last-visit in its Phase 3 VANISH 303 study, and that it expects to release top-line data earlier than previously reported. Ibrexafungerp (formerly SCY-078) is the first…

GTX ASTRID urinary incontinence (SUI)

GTx Announces Top-Line Results from Placebo-Controlled ASTRID Trial of Enobosarm in Women with Stress Urinary Incontinence

GTx, Inc. (Nasdaq: GTXI) today announced that the ASTRID Trial, a Phase 2 double-blind, placebo-controlled clinical trial of orally-administered enobosarm (3 mg or 1 mg) in post-menopausal women with stress urinary incontinence (SUI), did not achieve statistical significance on the primary endpoint of the proportion of patients with a greater than 50% reduction in incontinence episodes per day compared to placebo. The percentage of patients with a greater than 50% reduction after 12 weeks…

Myovant Sciences Combination Therapy in Women with Uterine Fibroids

Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids and Positive Results from Bioequivalence Study

Myovant Sciences (NYSE: MYOV), a clinical-stage healthcare company focused on developing and commercializing innovative therapies for women’s health and prostate cancer, today announced that LIBERTY 2, the second of two Phase 3 studies of once-daily relugolix combination therapy, met its primary efficacy endpoint and six key secondary endpoints in women with uterine fibroids…